This is a preview of the November 20 edition of Access Health-Tap here to get this newsletter delivered straight to your inbox. Here in Chicago, we have a Restaurant Week each year has released a study discrediting “pediatric sex rejecting procedures” for the treatment of gender dysphoria in children and teens. The study found “significant, long-term, and too often ignored or inadequately tracked” health effects from gender affirming treatments given to pediatric patients, according to a Wednesday news release from HHS, led by Health Secretary Robert F. Kennedy, Jr. The report’s authors included physicians from Duke University, University of South Florida and Baylor College of Medicine. The American Psychiatric Association participated in the review, but the American Academy of Pediatrics and the Endocrine Society refused HHS’ invitation to partake, according to the report. Health systems around the country are caught in the medical and political crossfires. As of August, at least 21 hospitals had discontinued some or all of their gender-affirming care services for transgender patients amidst increased pressure from President Donald Trump’s administration, NBC reported. The American Academy of Pediatrics and the American Medical Association released a joint statement on Wednesday, saying, “We reject selective or politically motivated interpretations of data that ignore the totality of research and clinical outcomes.” Click here for the full statement. You can view HHS’ report here. UMass Memorial Health Care She’s also the primary CEO of three of the eight medical groups in the Federation: the Mid-Atlantic Permanente Medical Group, the Permanente Medical Group in Northern California and the Northwest Permanente Medical Group in Oregon and part of Washington. Ansari oversees about 12, 000 physicians caring for a combined 6 million patients. We discussed how she’s preparing to support them into the future-especially as the Baby Boomer population ages, placing additional strain on an already-taxed health care system. Below, find some of her insights on how new care models and AI can lighten providers’ load. Editor’s Note: Responses have been lightly edited for length and clarity. How is The Permanente Federation planning to care for an aging population? We’re using a lot of different care models to look at this population, because [our plan] depends on the state. As an example, in Oregon, the birth rate is really low, and so the growth is in the Medicare line of business. What’s true across [all of our] markets is that we’re aging faster than we’re growing [the workforce], and so we have to really invest in caring for this older population. We know that for people over 65, close to 90 percent of them have at least one chronic medical condition, and 60 percent have at least two chronic medical conditions. People are living longer and they are carrying more disease burden. And so what we’re looking at from a population perspective is, how do we keep them living their best lives? How do we keep them healthy? How do we support them in this? Because they all look different, right? If you’ve seen one 80-year-old, you’ve seen one 80-year-old, because one might be playing tennis, another might be bedridden, and there’s everything in between. We have a few different pilots going on, but the general approach is moving care more and more upstream so that they don’t get the late-stage manifestation of their disease. If they have hypertension, [we want to ensure] that it’s under tight control, or if they have diabetes, that we’re controlling it so well that they don’t get hospitalized, because nobody wants to be in the emergency department. Frictionless, convenient access to care and care management systems help keep them healthy at home. That’s a mainstay throughout The Permanente Federation and all of our medical groups: care managers for chronic conditions. What we are doing differently right now is using AI to [identify patients that are at] the highest risk to be admitted, to have a fall, to have a heart attack, and really put wraparound services around them. We’re calling that Care Plus. We’ve been using that in Northern California, and we’re trying to spread it to some of the other markets. But the Care Plus model is basically a care team that includes a nurse, a pharmacist, a physician, a social worker and a care navigator. There are multiple [of those] groups of five that care for a population of patients that are at risk for getting sicker, and the AI alerts us to get involved, and they direct the right type of person on the team to address it. So if it’s a transport issue or a food insecurity issue, it might be the social worker. If it’s they’re running out of meds, it might be the pharmacist. Did Kaiser Permanente develop that AI tool internally, or are you working with a vendor? We do work with vendors on some of our AI tools. This particular AI tool is our own in-house AI tool [that] we use our electronic medical record for. We actually have 12. 6 million members across our entire enterprise, and use a predictive analytics model to determine who is most likely to get re-hospitalized, who’s more likely to deteriorate, and then alert the care team on what the gap is in terms of the need so that we can match them to the right member of the care team. It’s almost like AI is part of the care team-so we have a team-based approach, and AI is just one that is trying to match the patient to the right care team member. For most of their lives, patients over the age of 65 have been receiving care face-to-face, without much technological intervention. Are you concerned about integrating more digital tools into their care journey? Personally, I am not worried about it. They are not a monolithic group, and many of them are wearing wearables and are very tech savvy. They want real-time feedback. They want to have what we consider asynchronous interactions with their care team, where they can just [ask], “What do you think of this mole?” We piloted a [dermatology] app and had people send in pictures of their moles, and the AI algorithm helped tell them [if they were] going to have to see a doctor or if this could be managed with over-the-counter treatment. We had just as many older patients engaged in that as younger. In fact, the older patients are more likely to have some lesions that they’re more concerned about. So I’m very optimistic about our seniors embracing AI. We use AI in most of our clinic visits because we use Abridge and supplementing by looking for the metaphorical sunshine. Health care professionals are confronted with a lot of problems in their day-to-day: ill patients, declining reimbursement rates, staffing shortages. Naturally, a lot of our conversations focus on these issues; you have to examine them closely to find the solutions. But lately, I’ve really enjoyed hearing what industry leaders are excited about-what they feel is going right. This week, I saw some of those bright spots in my conversation with Dr. Alexa Kimball, president and CEO of Harvard Medical Faculty Physicians. Kimball told me that she sees progress when reflecting on her time in medicine, and that helps her keep a positive outlook. Here’s what she said: Editor’s Note: Responses have been lightly edited for length and clarity. “It’s been an incredible journey of watching the progress that medicine has made over the past 25 years, and an amazing privilege to be able to have been a part of it. “There are diseases that were so common and so problematic years ago, and today, this next generation of physicians has never even really seen the disease because it almost doesn’t exist anymore. “It’s been extraordinary to watch that, so I am very optimistic about the care that we bring to patients. We have to figure out how we support the physician enterprise effectively to bring the best care to patients, and AI has also made me optimistic about reducing some of doctors’ burdens to make them more effective. But we’re all in this together at the end of the day, and we’re not going to optimize the health care system unless all parts of it are really pulling the same direction, which, at the end of the day, should be about the care of the patients.” CEO Circle Insights from health care thought leaders around the world “A quiet paradox is unfolding in health care,” according to Dr. Lawrence Rosenberg, president and CEO of the Integrated Health & Social Sciences University Network for West-Central Montreal, and a member of Newsweek’s CEO Circle. Governments are focused on centralizing their health systems-but Rosenberg argues that they could become vulnerable to “intelligence bottlenecks” in the age of AI. Click here to read his thoughts.
https://www.newsweek.com/should-nursing-contracts-be-more-like-prix-fixe-menus-access-health-11084548
Tag Archives: decision-making
Historic Colorado River deal to conserve flows advances after winning key approval from state water board
A yearslong effort to purchase two of the most powerful water rights on the Colorado River has cleared another hurdle after the state water board agreed to manage the rights alongside Western Slope water officials. The Colorado Water Conservation Board voted unanimously Wednesday night to accept the two water rights tied to the Shoshone Power Plant into its environmental flow program. The approval is a critical piece in the Colorado River District’s $99 million deal with the owner of the aging plant in Glenwood Canyon Xcel Energy but the deal has faced pushback from Front Range water providers that fear the change could impact their supplies. Backers of the deal aim to make sure the water now used by the small hydroelectric plant and then put back in the river will always flow westward. “The importance of today’s vote cannot be overstated as a legacy decision for Colorado water and the Western Slope,” Andy Mueller, general manager of the Colorado River District, said in a news release. “It secures an essential foundation for the health of the Colorado River and the communities it sustains.” Colorado water officials hailed the decision as a monumental achievement for the state that will help protect the river and its ecosystem. The state’s instream flow program allows the Water Conservation Board to manage dedicated water rights for the health of rivers, streams and lakes. “Acquiring the Shoshone water rights for instream flow use is a once-in-a-lifetime opportunity to preserve and improve the natural environment of the Colorado River,” Dan Gibbs, the executive director of the Colorado Department of Natural Resources, said in a news release. One of the main sticking points during the hourslong meeting Wednesday was whether the board should manage the water rights with the River District. That would include decisions on how and when to require upstream users like Front Range utilities to send more water downstream. Generally, the board is the sole manager of water rights in its instream flow program, which the Shoshone rights are now a part of. Several Western Slope entities said they would withdraw their financial support from the purchase if the Colorado River District was not allowed to co-manage the right with the board. Local governments and other organizations across the Western Slope promised more than $16 million toward the purchase. Front Range water providers argued that the statewide board is the sole authority that can manage such rights and should have final decision-making power. The water board instead approved the co-management strategy, which means that the two authorities will decide together how to act when there is not enough water to meet the right’s obligations. The Colorado River District a taxpayer-funded agency that works to protect Western Slope water wants to purchase the Shoshone rights to ensure that water will continue to flow west past the plant and downstream to the towns, farms and others who rely on the Colorado River, even if the century-old power plant were decommissioned. A stream of Western Slope elected officials, water managers and conservation groups testified in support of the deal and the rare opportunity it presented. “The Shoshone call is one of the great stabilizing forces on the river a heartbeat that has kept our valley farms alive, our communities whole and our economies steady even in lean years,” Mesa County Commissioner Bobbie Daniel said, urging the board to approve the plan. The meeting on Wednesday came after weeks of extensive mediation between the River District and Front Range entities. However, the representatives from opposite sides of the Continental Divide could not come to a consensus on a way forward. Representatives from Front Range utilities have said repeatedly that they supported the purchase as a whole, but they stated concerns about the purchase changing the status quo on the river. The water rights connected to the plant are the oldest major water rights on the main stem of the Colorado River, which means that they must be fulfilled before any rights established afterward. Those include more junior rights held by Front Range utilities to divert water from the river and bring it under the Continental Divide to their customers. The plant’s rights can command up to 1, 408 cubic feet of water per second year-round, or about 1 million acre-feet a year enough water for 2 million to 3 million households’ annual use. The Water Conservation Board’s approval is one of several that must be acquired by the River District. The deal now must go through the state’s water court and its Public Utilities Commission. Along with the $16 million coming from Western Slope entities, the district will pay $20 million and the Water Conservation Board allocated another $20 million. The financial plan also includes $40 million awarded under the federal Inflation Reduction Act by the Biden administration, but that money remains frozen as part of the Trump administration’s broad halt to spending by the previous president.
https://www.canoncitydailyrecord.com/2025/11/20/colorado-river-shoshone-water-rights-vote/
Quarterly profit slide at Target hints at a challenging holiday season for the retailer
By ANNE D’INNOCENZIO NEW YORK (AP) Target’s third-quarter profit tumbled as the retailer struggles to lure shoppers that are being pressed by stubbornly high inflation. The Minneapolis company said Wednesday that it expects its sales slump to extend through the critical holiday shopping season. The company also announced that it’s planning to invest another billion dollars next year to remodel stores, build new ones, increasing the total cost for the makeover to $5 billion. Investors have punished Target’s stock recently, sending it down 43% over the past year. Shares were essentially flat in early trading Wednesday. Turning around the 19% profit slide in the most recent quarter is the latest challenge for incoming CEO Michael Fiddelke, a 20-year company veteran who is replacing CEO Brian Cornell in February. The handover arrives as the retailer tries to reverse a persistent sales malaise and to revive its reputation as the place to go for affordable but stylish products. Comparable sales those from established physical stores and online channels dipped 2. 7% in its latest three-month period. That’s worse then the 1. 9% drop in the previous quarter and the third straight quarterly decline. Target’s troubles stand in stark contrast to rival Walmart, the nation’s largest retailer, which is thriving. Walmart reports on its most recent quarterly performance Thursday. Target announced in October that it was eliminating about 1, 800 corporate positions to streamline decision-making and accelerate company initiatives. The cuts represent about 8% of Target’s corporate workforce. To pump up sales, Target is offering more than 20, 000 new items, twice as many as last year, and it has lowered prices on thousands of groceries and other essential items. “The environment around us continues to evolve, whether it’s shifting consumer demand, changing competitor dynamics, or broader macroeconomic pressures,” Fiddelke said on an earnings call Wednesday. ”But let me be clear. We are not waiting for conditions to improve. We are driving the change ourselves right now.” With about 1, 980 U. S. stores, Target has struggled to find its footing since inflation caused Americans to curtail much of their discretionary spending. At the same time, Target customers have complained of messy stores lacking the budget-priced niche that long ago earned the retailer the nickname “Tarzhay.” Consumer boycotts since late January, when Target joined rival Walmart and a number of other prominent American brands in scaling back its corporate diversity, equity and inclusion initiatives, have compounded the predicament. Other, more recent macro headwinds, are buffeting the entire retail sector. For almost a year, retailers have struggled to navigate President Donald Trump’s wide-ranging tariffs on imports and his immigration crackdown that threatened to shrink the supply of workers available to U. S. companies. The just ended 43-day federal shutdown is expected to be another drag on an economy. Government contract awards have slowed and many food aid recipients have seen their benefits interrupted, both of which can cut into consumer spending at places like Target. Fiddelke told reporters that the company saw a weaker September but he said it was “tricky for us to isolate” the different factors behind that. The retailer’s profit fell to $689 million in the three-month period ended Nov. 1, or $1. 51 per share. Adjusted per share results added up to $1. 78. That is better than the $1. 71 that Wall Street was expecting, according to a poll by FactSet, but below the $1. 85 per share the company earned in the same period last year. Sales fell 1. 5% to $25. 27 billion, just shy of analyst projections. Sales gains in food and beverages were offset by continued weakness in discretionary goods, with anxious shoppers focused increasingly on buying essentials, even during the holidays. For example, customers this year customers bought candy and costumes for Halloween, but spent less on decorations, said Rick Gomez, chief commercial officer for Target. Gomez thinks they will make similar tradeoffs during the winter holiday season. “We think the consumer will prioritize what goes under the tree versus what goes on the tree,” he said. Target also announced a partnership with OpenAI on Wednesday that will let users browse Target items through the tech company’s app ChatGPT. When customers are ready to buy, they’ll be directed to the Target app. For the fourth quarter, Target expects that comparable sales will decline by low single digits. For the full year, it now expects earnings per share to be in the $7 per share to $8 per share range, down from its earlier forecast of $7 to $9.
https://www.courant.com/2025/11/19/target-results/
The Decisions You Don’t Know You’re Making: QCon Keynote Explores Hidden Choices in Engineering
Engineering teams make their most consequential decisions not in architecture reviews or sprint planning, but through invisible choices embedded in metrics, defaults, and everyday behaviors. In their QCon San Francisco 2025 keynote, Shawna Martell and Dan Fike challenged the industry’s focus on documented decision-making while the decisions that truly shape systems and culture go unrecognized. The talk invited engineering leaders to ask uncomfortable questions: What behaviors do our CI/CD pipeline speeds actually incentivize? Which defaults have we inherited without examination? What are we measuring, and what behaviors does that measurement reward? For organizations struggling with poor outcomes or culture issues that seem disconnected from technical choices, the hidden decision analysis offers a new lens. Rather than prescribing solutions, the speakers offered a diagnostic framework for recognizing hidden decisions. Their approach echoes broader industry conversations about Architecture Decision Records. The key insight: hidden decisions can be named and examined once teams learn to identify them. Hidden behaviors and choices have a broad impact on the engineering work we eventually see “Sometimes, as engineers, the right decision for us is not to build,” they said. The hidden decision to build implicitly accepts the costs and risks of building and maintaining something new. As developers, we often love to solve problems with code. But we never stop to ask ourselves, “Is this the correct solution?” when, many times, it isn’t. The problem, they explain, is that engineering organizations measure outcomes such as features shipped or system uptime but rarely examine the decision quality that produced those results. This phenomenon creates a dangerous blind spot where teams optimize for the wrong things without realizing it. Examples of metrics that, when measured, can drive the wrong behavior The speakers illustrated their thesis with CI/CD pipelines. When pipelines run slowly, engineers aren’t just waiting longer for builds to complete. They start exhibiting behaviours like bundling PRs together. As a result, instead of having small, manageable PRs, we have massive changes that are harder to review, rubber-stamped approvals, and deteriorating quality. Per the speakers, we should ask ourselves, “What behaviours do we want to incentivise, and how can our tooling support that?”. The speakers then termed “the default trap.” Teams accept defaults and act on them whether they consciously accept them or not. They cited an example of a team that decided to build its own platform instead of using an existing one within the organization, even though the existing one already solved a similar problem, simply because the default in that organization was for every team to own its own stack. In this case, team ownership became the “default” and was not challenged until Martell explicitly called it out. “We need to name the defaults to be able to explicitly accept or reject them as required”. The most insidious hidden decisions emerge from metric selection. The speakers described how, during an architectural change, measuring events sent to Kafka led to massive unnecessary traffic because teams optimized for the metric rather than the underlying need. “Most events were not even required,” they explained. Similarly, measuring career progress through title changes obscures the real decision about career strategy-whether engineers are actually making progress in a direction that makes sense for them. Engineers build skills that lead to specialization, which builds their reputation and the value they provide, which in turn determines their roles, until changing direction becomes risky. “Once you’re building that view of yourself, deciding to change is risky,” and so identifying these hidden decisions in real time is even more crucial.
https://www.infoq.com/news/2025/11/hidden-decisions/?utm_term=global
Tech, digital skills unlock UK’s manufacturing potential: Barclays
U.K. business leaders say that the country’s manufacturing potential remains strong, but significant investment in technology adoption and digital skills is essential to prevent further decline. This insight comes from a new report by Barclays Bank (NASDAQ: BCS) and The Manufacturer, titled **“Mind the Gap: Closing the productivity divide in UK manufacturing.”**
Released last week, the report is based on surveys and interviews with more than 100 U.K. manufacturers. It offers a cautiously optimistic view from the country’s manufacturing leaders, who largely agree that while productivity has been in decline, there is a path forward—one many manufacturers have already started to pursue.
### The Current State of U.K. Manufacturing Productivity
The latest data from the U.K.’s Office for National Statistics (ONS) shows that productivity, measured by output per hour, is 10% below the G7 average. Germany, a traditional manufacturing powerhouse, outperforms the U.K. by a full 16%. These figures align with industry leaders’ perceptions: more than half (56.4%) believe U.K. manufacturing productivity is declining, while 19% are unsure.
### Key Causes of Productivity Challenges
The report identifies several factors contributing to the productivity gap:
– **Skills and Workforce Challenges (56.5%)**
– **Slow Technology Adoption (40%)**
– **Supply Chain Inefficiencies (31.3%)**
– **Regulations (10%)**
A lack of digital skills is part of the workforce challenge, but the primary concern is the difficulty in finding workers willing to engage in manufacturing roles. The sluggish adoption of technology also remains a top concern. Cost is cited as the biggest barrier for smaller companies, with one CEO commenting that these firms often lack “financial headroom to trial new systems without guaranteed ROI.”
### Technology Adoption: A Critical Differentiator
The report highlights a wide disparity in digital transformation across manufacturers. Some have embraced integrated platforms to drive decision-making, while others rely on fragmented systems or even manual record-keeping. This gap directly affects their ability to identify inefficiencies and react in real time.
Interestingly, the report also notes a lack of a consistent, widely accepted definition of what “manufacturing productivity” actually means, which complicates benchmarking efforts. Despite these challenges, nearly half of respondents (49.6%) plan to increase their digital transformation efforts within the next 12 months—making it the top priority.
### Priorities for the Year Ahead
Following digital transformation, the next highest priorities for manufacturers over the coming year are:
– **Upskilling/Reskilling Staff (45%)**
– **Supply Chain Optimisation (29%)**
– **Enhanced Data Management (26%)**
### Conclusion
Overall, the research paints a mixed picture for the U.K. manufacturing sector. The report concludes:
> “The direction of travel is positive: manufacturers are investing, innovating and building momentum. Yet the challenge cannot be underestimated. Without continued focus on skills, technology adoption and process efficiency, the UK risks losing pace with global competitors.”
—
**Read the full report here.**
**Watch:** [What Drives Innovation in Frontier Tech?](#)
https://bitcoinethereumnews.com/tech/tech-digital-skills-unlock-uks-manufacturing-potential-barclays/
The Data Fog Envelopes Jobs, Prices And Tariffs
MV Financial
*1.03K Followers*
**Weekly Summary: Politics, Economy, and the Impact of Absences**
This week has been full of news spanning politics, the economy, and much more. However, it has also been a week where notable absences have loomed large. The ongoing data fog has already begun to affect the central bank’s traditionally smooth decision-making process, evidenced by dissenting votes in each of the last three FOMC sessions.
Additionally, the Supreme Court weighed in with what appeared to be a rather caustic critique of the Trump administration’s legal authority regarding the barrage of tariffs imposed since taking office. Over this period, the average tariff on goods entering the US has risen sharply—from 2.4 percent to 17.9 percent.
Typically, this week would have marked Jobs Friday, when the Bureau of Labor Statistics releases employment data, but the theme of absences remains prevalent as this important report was notably delayed.
—
**About MV Financial**
MV Financial is a Washington, DC-area asset manager offering investment advisory services through MV Capital Management, a Registered Investment Advisor. We specialize in deep research across a wide range of asset classes and investment vehicles, aiming to transform knowledge into actionable investment solutions tailored for individual, family, and institutional clients.
—
**Comments**
*Recommended For You*
https://seekingalpha.com/article/4840816-data-fog-envelopes-jobs-prices-tariffs?source=feed_all_articles
Blanket Informed Consent for Biologics Could Be Deadly. A Warning From Dr. Sherri Tenpenny
**Guest Post by Dr. Sherri TenPenny**
There’s a linguistic shift happening inside the walls of hospitals, surgical centers, and outpatient clinics—one that most people won’t notice until it’s too late. The word “vaccine” is vanishing from medical consent forms. In its place is a far broader, far murkier term being used: **biologics**.
### Let’s Clarify Some Definitions
**Biologics** refers specifically to a class of therapeutic drugs and medical products that are produced from living organisms or their components (e.g., made from proteins, organ cells, tissues, blood, tallow, gelatin, glycerol, etc.). Biologics are specifically regulated medical products that are made from or contain components of living organisms.
On the other hand, **biogenics** is a broader, more general term meaning produced by living organisms or biological processes. It could be anything made by a living organism—plants, animals, bacteria, fungi, etc.
**Examples of biogenics:**
– Tree resin (produced by plants)
– Coral or seashells (made by marine animals)
– Methane (from decaying organic matter)
– Alcohol (from yeast fermentation)
Therefore, all biological products are biogenic, but not all biogenic materials are biological products.
That means many new, modern medicines labeled “cutting-edge,” from mRNA injections to bioengineered cells, fall into the category of medically regulated biogenic products.
—
### The Redefinition of Medicine
At first glance, it may sound harmless. But buried in the word salad of admission paperwork is a seismic change you might be agreeing to without realizing it.
As a patient in a hospital, you could be injected, infused, or implanted with a biologic product you never specifically discussed with your treating physician—simply because the consent form used a broad term like “biologics” or “biogenics” and you didn’t fully understand the scope of that word.
It’s not that the hospital is secretly adding products; rather, the way the consent forms are worded gives them legal permission to use FDA-approved biologics or biologic materials when they are deemed medically necessary, without first discussing the pros and cons of the product.
You can view the full list of biologics on the FDA’s website. Vaccines are listed among the “approved biologics.” If you blindly sign a consent to receive a biologic, you’ve opened the door to a sweeping range of interventions that go far beyond what most would knowingly authorize.
—
### The Purpose and Erosion of Informed Consent
The purpose of requiring informed consent is to promote the autonomy of the individual in medical decision-making. It is a legal doctrine that supports many of our cherished American ideals about our rights as individuals.
For decades, medical care has been governed by the principle that patients must be fully informed, fully aware, and provide informed consent for every healthcare procedure. It was more than a legal requirement; it has long been an ethical cornerstone.
However, as PubMed’s 1996 article, *Legal and Ethical Myths About Informed Consent*, reminds us, even the foundation of informed consent came from a murky beginning. The phrase “informed consent” first appeared in a 1957 California case and was adopted verbatim, without attribution, from an amicus curiae brief submitted by the American College of Surgeons.
Over time, the standard for truly informed consent has quietly been eroded. In many hospitals and clinics, informed consent forms have become little more than a formality: a few checks in digital checkboxes and a scribbled signature on an iPad.
These consent forms are often buried within pages of fine print drafted by attorneys, intentionally dense and difficult to read. Even patients who try to understand the language find it nearly impossible to decipher.
Today, the forms no longer use plain language. Instead of asking, “Do you consent to receive the influenza vaccine or a COVID jab?”, the consent form may now ask if you consent to the use of **biologic agents**.
The assumption is that you, the patient, understand that vaccines are biological agents. This raises the question: **Is the confusing change in language intentional?**
—
### “Medically Necessary Biologics” – The Next Frontier
There is a push to categorize biologics as *medically necessary*. Once that phrase becomes standard, it reframes these products as non-optional. That’s a linguistic shift that carries enormous implications.
If something is medically necessary, then refusing it becomes extremely difficult.
Now imagine being prepped for surgery. You’re told you must sign a standard consent for “biologic products as necessary during the procedure.” You sign, thinking it refers to anesthesia, sutures, IV fluids, perhaps antibiotics.
But your body then becomes an open field for whatever the institution or your doctor regards as necessary: a flu shot, a pneumonia shot, a pertussis shot, a monoclonal antibody infusion, or plasma/blood (perhaps from a COVID-vaccinated donor).
You may never know what went into your body unless you ask for the record.
—
### What Do Biologics Include?
According to the FDA and Congressional Research Service documents, biologics encompass:
– Vaccines
– Monoclonal antibodies
– Gene therapy
– Whole blood and plasma
– Stem cells and T-cells
– Recombinant proteins
– Growth factors
The side effects of biologics vary depending on the specific product and how it is administered. Because these therapies are derived from living systems and often target the immune system, they can produce a wide range of reactions—from mild and localized to serious or life-threatening.
Examples of side effects include:
– Allergic or hypersensitivity reactions
– Injection site redness, swelling, or pain
– Infusion reactions such as flushing, shortness of breath, or a sudden drop in blood pressure
– Chills, weakness, diarrhea, nausea, vomiting, rash, itching, and high blood sugar
– More serious effects such as low blood pressure, anaphylaxis, serious infections, cancer, autoimmune reactions, blood clots, heart failure, bleeding disorders, and more
Each biologic drug has its own safety profile, and not all patients will experience these reactions. But because biologics act deeply within the body’s immune and cellular systems, their side effects can be complex, unpredictable, and sometimes severe.
These products are not something you should be given without knowing the risks!
—
### The Anesthesia Loophole
Anesthetized patients cannot give or withdraw consent in real-time. Hospitals know this, and legal teams have prepared for it.
That’s why pre-operative consent forms now carry generalized clauses authorizing “treatment using biologic materials.” The rationale sounds protective: “We need flexibility in case of complications.”
The reality is exploitative: “We can administer what we deem appropriate.”
Under this loophole, you could receive a biologic without your explicit approval. Once it’s in your body, it cannot be undone.
While this remains only a theoretical concern at this time, as AI increasingly takes over healthcare and personal options continue to be reduced, it is distinctly possible.
I found court cases where a patient received a biologic without specific consent. While I didn’t find a published U.S. case that squarely says: “Because of the single word biologics in a blanket consent, a sedated patient got a biologic they would have refused,” these cases demonstrate the core risk is real.
—
### What You Must Do
We are living in a time when words have become deceptive—from politics to healthcare. To protect yourself, you must re-establish your authority over your own body.
Here’s where to start:
– **Read every word.** Never sign a consent form that contains vague terms like “biologics,” “biogenics,” or “cell-based therapies” without a full explanation from your doctor(s).
– **Ask direct questions.** Ask out loud: “Does this include vaccines, gene therapies, or blood products?” Write their answers and whether you agree or disagree.
– **Refuse in writing.** On both digital and paper copies, clearly state: “I do not consent to the administration of vaccines, biologics, or other synthetic materials.”
– **Get a copy.** Always request a printed copy or photo of your signed form, especially if it was done on an iPad.
– **Have an advocate.** Assign a trusted person to reiterate your refusal verbally and in writing if you are incapacitated. If you don’t have a close friend or family member to help, hire someone from GraithCare.com—they are knowledgeable and worth every penny.
– **Document everything.** After discharge, review your medical record and confirm what was administered. Side effects or complications may not materialize for weeks or months.
This is not paranoia; this is precautionary and wise self-care. The same level of attention you’d give to a financial contract should apply even more importantly to your medical care.
—
### Bodily Autonomy Is a Spiritual Battle
At its heart, this is about sovereignty. The right to decide what enters your body—what merges with your cells—is not just a medical decision, it’s a moral and spiritual obligation.
Scripture says our bodies are temples of the Holy Spirit, not laboratories for untested technologies. To surrender consent to vague, corporate-crafted terms like “biologics” is to give the keys away to your own temple.
I believe every human being deserves the dignity of true informed consent—not coerced compliance through deceptive wording.
—
### Closing Thoughts
We are a litigious society, and physicians are always concerned and on the defensive about avoiding lawsuits.
The timeless advice from that 1996 article on how you can best be perceived and help your patient’s decision-making process:
*“Treat patients like people, act sensitively and compassionately, and most of all, talk to patients. Have a conversation, have several; remember that this is a process. In this process, you will gradually come to know your patient’s decision-making style. Furthermore, do not press patients to decide quickly. Do not make them think that you do not have time for them. Because if you do, regardless of how much information they are given, they are going to be angry, and another name for an angry patient is plaintiff.”*
So please, **before you sign anything:**
– Stop.
– Read.
– Ask.
– Refuse if you must.
– Line out what you don’t agree with, initial it, and date it.
Your signature implies permission.
—
**About Dr. Sherri J. Tenpenny**
Dr. Tenpenny is the founder of Tenpenny Integrative Medical Center, a clinic providing integrative medicine throughout Cleveland and Northeast Ohio. She received her training as an osteopathic medical doctor at Kirksville College of Osteopathic Medicine in Missouri.
Widely regarded as one of the most knowledgeable and outspoken physicians on vaccine safety, Dr. Tenpenny has been featured on hundreds of radio and national television programs. She has authored several books and contributed chapters to many more. Her articles have been published in at least 14 languages.
Trained in Emergency Medicine, Osteopathic Manipulative Medicine, and Integrative Medicine, she is also the founder of multiple businesses, including the nationally recognized Tenpenny Integrative Medical Center and the Tenpenny Health Restoration Centers.
—
*This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider for medical decisions.*
https://www.thegatewaypundit.com/2025/11/blanket-informed-consent-biologics-could-be-deadly-warning/
china Magnetic Stirrer Market Outlook 2025: Forecasting Growth in a Time of Economic and Policy Shifts
**Magnetic Stirrer Market Outlook**
**Base Year:** 2024
**Forecast Years:** 2025-2035
—
The primary aim of this report is to provide in-depth industry data to assist decision-makers in making critical investment decisions while identifying potential changes and gaps in the Magnetic Stirrer Market. To achieve this, the report examines the historical trends and forecasts future development across different geographical regions.
This comprehensive analysis includes coverage of future technologies, technological innovations, and advancements within the industry. The study further offers an in-depth analysis of sales volume, market share, revenue, competitive landscape, and SWOT analysis to help readers gain a clear understanding of the market dynamics.
—
### Key Industry Insights
The research focuses on various market types, major players, on-premises availability, and applications. It evaluates the Magnetic Stirrer Market’s primary product and application categories, alongside the key market segments, projecting their growth over the forecast period.
Additionally, the report presents crucial information on emerging features expected to influence market growth during the forecast timeline.
For an in-depth analysis, you can request a free sample copy of the report, which includes a brief overview, table of contents, regional analysis, top players, revenue analysis, and research methodology.
—
### Top Key Companies in the Magnetic Stirrer Market
– DWK Life Sciences Inc.
– 2mag AG
– Scilogex LLC
– Thermo Fisher Scientific Inc.
– PAW Bioscience Products LLC
– IKA-Werke GmbH & Co. KG
– Thomas Scientific Inc.
– Yamato Scientific America Inc.
– Torrey Pines Scientific Inc.
– Labnet International Inc.
—
### Market Scope and Growth Analysis
The Magnetic Stirrer Market is rapidly expanding due to the growing need for data-driven decision-making across multiple industries. Its scope spans various sectors such as healthcare, technology, retail, and finance, offering insights into consumer behavior, market trends, and the competitive landscape.
The global market research industry is projected to experience significant growth driven by advancements in artificial intelligence (AI), big data analytics, and digital tools that enable more accurate and real-time insights. Moreover, the rise of emerging markets and increased adoption of online research methods further contribute to market expansion, making magnetic stirrers an integral component of business strategy and innovation.
—
### Competitive Dashboard
This report provides detailed information on the commitments of key companies, supply and demand analyses, and the increase in market share for Magnetic Stirrers. The primary market players are analyzed thoroughly from various perspectives, including financial status, production volume, product descriptions, and company profiles.
Furthermore, the report covers companies’ trade objectives, SWOT analyses, revenue streams, product enhancements, and more. Leading organizations employ various strategies such as partnerships, collaborations, mergers and acquisitions, and new product launches to maintain a substantial market share.
The report also explores industrial layout characteristics, regional trends, and applicable industry regulations. Visual aids such as maps, bar graphs, and pie charts communicate market attributes clearly.
—
### Comprehensive Market Data
To support strategic business decisions and new product launches, this report combines both primary and secondary research methods. It covers market trends, sales channel research, upstream raw material analysis, and downstream demand analysis.
The research further evaluates the profitability potential of products, providing valuable estimates for industry participants to help them grow their businesses and innovate within the Magnetic Stirrer Market.
—
### Market Report Segmentation
The market report offers a detailed analysis of segments, highlighting those with the largest market shares. Forecasts cover the period from 2025 to 2035, with 2024 serving as the base year.
**Segments include:**
– **By Product Type:** Regular Magnetic Stirrer, Hot-Plate Magnetic Stirrer, Multi-Position Magnetic Stirrer
– **By Display:** Analog, Digital
– **By Application:** Pharmaceutical, Chemical and Biotech Laboratories, Academic and Research Institutes
– **By Region:** North America, Europe, Asia Pacific, Latin America, Middle East & Africa
—
### Market Trends, Analysis, and Forecast till 2032
Download the PDF report brochure to access a complete list of key players and in-depth regional analysis.
—
### Major Highlights of the Market
– Detailed coverage of all Magnetic Stirrer Market segments.
– Competitive assessment focusing on key rival portfolios and regional expansion strategies.
– Comprehensive geographic mapping of market presence and growth opportunities.
– Identification of emerging market trends and growth drivers.
—
### Top Winning Strategies
Leading companies adopt a variety of business strategies, including product innovation, collaborations, and mergers & acquisitions, to strengthen their market position.
—
### What Unique Insights Does this Report Offer?
This report answers critical questions such as:
– What is the size of the sales opportunity?
– Which regions offer the best sales potential?
– Which market segments are the most attractive?
– Who are the top players, and what is their market positioning?
– How complex is the current business environment?
– What are the primary factors influencing the market?
—
### About Us
Prophecy Market Insights is a premier provider of market research services, delivering insightful and actionable reports across various industries. Our experienced team of analysts and researchers offers accurate and reliable market intelligence to help businesses make informed decisions and remain competitive.
Our research reports cover a broad array of topics, including industry trends, market sizing, growth opportunities, and competitive landscapes. Prophecy Market Insights is dedicated to providing high-quality research that enables clients to achieve their strategic goals and objectives.
—
### Contact Us
**Prophecy Market Insights**
Website: [Insert Website URL]
US Toll-Free: +1 689-305-3270
—
*For more information or to request a sample report, please contact us at the details above.*
https://www.prnewsreleaser.com/news/117674
japan Cancer Diagnostics Market Intelligence Report: Recession Readiness and Tariff Implications
**Cancer Diagnostics Market Outlook**
**Base Year:** 2024
**Forecast Years:** 2025-2035
—
### Overview
The primary aim of this report is to provide in-depth industry data to assist decision-makers in making critical investment decisions and identifying potential changes and gaps in the Cancer Diagnostics Market. To achieve this, the research analyzes both the historical development of the market and forecasts future growth by geographic regions.
The report also covers emerging technologies, technological innovations, and advancements within the industry. Detailed analysis of sales volume, market share, revenue, competitive landscape, and SWOT analysis is included to help readers gain a comprehensive understanding of the sector.
—
### Key Industry Insights
This research was conducted with a focus on market types, major players, on-premises availability, and various applications. It examines the main product and application categories within the Cancer Diagnostics Market, calculating the growth of each segment over the forecast period.
Additionally, the report highlights critical features expected to emerge during the forecast years, along with their potential impact on market growth.
For an in-depth analysis, you can request a **free sample copy** of the report, which includes a brief overview, table of contents, regional analysis, top players, revenue analysis, and research methodology.
—
### Leading Companies in the Cancer Diagnostics Market
– Thermo Fisher Scientific Inc.
– Hoffmann-La Roche Ltd.
– Abbott Laboratories
– Becton Dickinson and Company
– Agilent Technologies Inc.
– Roche Diagnostics GmbH
– QIAGEN N.V.
– Illumina Inc.
– Eli Lilly and Co.
– Philips Healthcare Informatics Inc.
—
### Market Scope and Growth Analysis
The Cancer Diagnostics Market is rapidly expanding, driven primarily by the growing demand for data-driven decision-making across multiple industries. Its scope extends beyond healthcare to include technology, retail, and finance sectors, offering valuable insights into consumer behavior, market trends, and competitive landscapes.
The global market is projected to witness significant growth, supported by advancements in artificial intelligence (AI), big data analytics, and digital technologies, which enable more accurate and real-time insights. Rising adoption of online research methodologies and expansion into emerging markets also contribute to this upward trajectory, positioning cancer diagnostics as a critical component of business strategies and innovation.
—
### Competitive Landscape
The report provides a detailed analysis of the key industry players, including their financial status, production volumes, product descriptions, and organizational profiles. It also covers company objectives, SWOT analyses, revenue streams, product launches, collaborations, mergers and acquisitions, and other strategic initiatives.
Competitive positioning is enhanced through various strategies such as partnerships and innovation, helping companies maintain and grow their market share.
Market characteristics and trends are visually presented through maps, bar graphs, pie charts, and other infographics to facilitate easy understanding.
—
### Additional Market Insights
– Comprehensive industry data to support business decision-making and new product development.
– Analysis of market trends, sales channels, upstream raw materials, and downstream demand.
– Profitability analysis to help industry participants strategize effectively.
– Geographic and segment-wise analysis to identify lucrative opportunities and challenges.
—
### Market Segmentation
The report segments the Cancer Diagnostics Market based on the following:
**By Method:**
– Enzyme-Linked Immunosorbent Assay (ELISA)
– Enzyme-Linked Fluorescent Assay (ELFA)
– Polymerase Chain Reaction (PCR)
– Next Generation Sequencing (NGS)
– Immunohistochemistry
– Microarray
– Imaging Techniques:
– Magnetic Resonance Imaging (MRI)
– Computed Tomography (CT scan)
– Positron Emission Tomography (PET)
– Ultrasound
– Mammography
– Biopsy
– Others
**By Disease Indication:**
– Breast Cancer
– Colorectal Cancer
– Cervical Cancer
– Lung Cancer
– Prostate Cancer
– Skin Cancer
– Blood Cancer
– Kidney Cancer
– Liver Cancer
– Pancreatic Cancer
– Ovarian Cancer
– Others
**By Region:**
– North America
– Europe
– Asia-Pacific
– Latin America
– Middle East & Africa
—
### Market Highlights
– Thorough coverage of all Cancer Diagnostics Market segments.
– Competitive analysis of key players and their regional expansions.
– Detailed geographic landscape of the market.
– Identification of upcoming trends and promising market opportunities.
—
### Top Winning Strategies
The report identifies leadership strategies employed by top companies, including organizational restructuring, collaborations, mergers and acquisitions, and launches of innovative products aimed at securing a competitive advantage.
—
### Unique Insights Offered by This Report
This comprehensive report answers critical questions such as:
– How large is the sales opportunity in the Cancer Diagnostics Market?
– Which regions provide the best sales prospects?
– What are the most attractive market segments?
– Who are the top players, and what is their market positioning?
– What is the complexity of the current business environment?
– What are the key market-driving and restraining factors?
—
### About Us
**Prophecy Market Insights** is a leading provider of market research services, delivering insightful and actionable reports across various industries. With a team of seasoned analysts and researchers, we provide accurate, timely, and reliable market intelligence to help businesses make informed decisions and stay ahead of their competition.
Our research covers a broad spectrum of topics, including industry trends, market size, growth opportunities, competitive landscapes, and more. Prophecy Market Insights is committed to excellence, ensuring clients achieve their strategic goals with our high-quality research.
—
### Contact Us
**Prophecy Market Insights**
Website: [Insert Website URL]
US Toll-Free: +1 689 305 3270
—
*Download the PDF Report Brochure to access the complete list of key players and detailed market insights.*
https://www.prnewsreleaser.com/news/117579
Rio Ferdinand delivers verdict on Senne Lammens after watching him make debut in ‘graveyard’ role for Manchester United
Manchester United legend Rio Ferdinand has shared his thoughts on Senne Lammens after the goalkeeper’s impressive debut against Sunderland. The Belgian, who joined Old Trafford from Royal Antwerp this summer, kept a clean sheet as Manchester United secured a vital 2-0 victory over the Black Cats on Saturday.
Lammens’ performance was widely praised by fans, who saw him as a breath of fresh air following the club’s recent struggles between the posts. Thanks to his confident start to life in England, Lammens is now expected to become the first-choice goalkeeper for Ruben Amorim’s side.
### Ferdinand Praises Lammens’ Debut
Speaking on his YouTube show, *Rio Ferdinand Presents*, the former Manchester United defender commented on Lammens’ impressive display. He highlighted the confidence the Belgian would have instilled in the Manchester United defenders.
“That [performance from Lammens] must instil so much confidence in the backline and then it spreads through the team,” Ferdinand said. “You know the feeling when a goalkeeper comes out and claims a ball into the box? That feeling of looking down at him when he’s on the floor and getting up and going, that’s my goalkeeper man. I don’t think United have been able to say that for a while because there’s been so many different mistakes and questionable decision-making. He just looked very, very secure.”
Ferdinand also shared how Lammens’ performance lived up to what Thibaut Courtois had told him about the young keeper. He noted that the goalkeeping position at Manchester United has often been a challenging place for many to thrive.
“Courtois left me a voice note a few weeks ago when we made the decision to sign him, and a lot of it was about him [Lammens] being a stable, steady keeper, huge talent, and massive potential,” Ferdinand added. “He looked exactly like what Courtois said in that voice note. By the way, Man United’s goalkeeping position has been a place that has been a graveyard for many players.”
### Lammens’ Record at Antwerp
Prior to joining Manchester United, Senne Lammens made 44 appearances across all competitions for Royal Antwerp last season, securing 10 clean sheets.
### What’s Next for Manchester United in the Premier League?
The win over Sunderland lifted Manchester United to 10th place in the Premier League table, with 10 points from seven games. After the upcoming international break, Ruben Amorim’s men face a tough challenge away at Liverpool’s Anfield.
Reigning Premier League champions Liverpool enter the game on the back of three consecutive defeats in all competitions, the latest being a loss against Chelsea at Stamford Bridge. Manchester United will look to capitalize on Liverpool’s recent dip in form, but a win is far from guaranteed in this fiercely contested derby.
Liverpool and Manchester United will go head-to-head on October 19, battling fiercely to secure maximum points in one of English football’s most iconic fixtures.
https://www.sportskeeda.com/football/news-rio-ferdinand-delivers-verdict-senne-lammens-watching-make-debut-graveyard-role-manchester-united
